Novartis' Unbranded Diovan Ads Draw FDA Scrutiny
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has concerns that the unbranded ad, which is connected to a disease awareness program, too heavily references Novartis. The company has its own concerns that unbranded ads may not be effective in the anti-hypertensive market.